Earnings call transcript: Indutrade AB sees mixed Q2 2025 results

Indutrade AB reported a mixed Q2 2025, with earnings per share decreasing 12% and organic sales falling 4%, which led to a 4.26% decline in its stock price during pre-market trading. Despite a lower EBITA margin, the company maintained a positive book-to-bill ratio for the second consecutive quarter, improved its net debt to EBITDA ratio to 1.5, and completed four acquisitions contributing positively to EBITDA. Management anticipates sales improvement in the second half of 2025 through continued cost adaptation and further M&A, supported by a strong financial health rating, though challenges persist in sectors like infrastructure and construction amid ongoing market uncertainty.

Analysis

Indutrade AB's second-quarter 2025 results revealed a surface-level contraction, with a 12% year-over-year decline in earnings per share and a 4% fall in organic sales, which prompted a 4.26% pre-market share price drop. However, management commentary provides crucial context, attributing the sales decline to fewer working days and exceptionally strong prior-year comparisons, especially large orders for its Life Science division; adjusting for these factors would have resulted in flat underlying sales. Despite the EBITA margin compressing to 13.7% from 14.8%, the company demonstrated operational progress with a positive book-to-bill ratio for the second consecutive quarter, an order backlog nearly restored to prior-year levels, and a stable gross margin at 35.3%. Financially, Indutrade strengthened its balance sheet, improving its net debt-to-EBITDA ratio to 1.5 from 1.7. While the M&A pace slowed, with four acquisitions completed, the company maintains a "very strong" pipeline and anticipates an acceleration in the second half of the year. The outlook is cautiously optimistic, guiding for sales improvement in Q3 and Q4, though persistent weakness in the infrastructure and construction sector remains a significant headwind.

Key Decisions for Investors

• Given the stock is trading near its 52-week low and is deemed fairly valued, investors should weigh the negative headline figures against positive underlying metrics like the strong book-to-bill ratio and improving debt profile.
• The primary catalyst for upside is the execution of the M&A strategy; monitor deal announcements in the second half of 2025, as management's confidence in a 'very strong' pipeline could drive future accretive growth.
• Closely track performance in the infrastructure and construction segment, as management has explicitly identified it as a persistent area of weakness that could offset gains in other business areas.
• Investors should anticipate continued margin pressure until organic sales growth resumes, but note that the company is actively managing costs with a target of achieving negative organic expense growth.